Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + pegylated liposomal doxorubicin
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), and pegylated liposomal doxorubicin (PLD), a modified form of the chemotherapy drug doxorubicin. Bevacizumab works by inhibiting angiogenesis, reducing blood vessel formation that supplies tumors with nutrients and oxygen. Pegylated liposomal doxorubicin is doxorubicin encapsulated in liposomes and treated with polyethylene glycol, which allows the drug to remain in circulation longer and increases delivery to tumor sites while reducing toxicity to normal tissues.
- Brand names
- Caelyx
- Other names
- bevacizumab and pegylated liposomal doxorubicinbevacizumab and Doxilbevacizumab and Caelyx
02
Targets
Beyond the preview
Go deeper on bevacizumab + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + pegylated liposomal doxorubicin.